Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-based Compensation (Tables)

Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2018

Schedule of stock-based compensation related to all of the entity's share-based payments

Total stock-based compensation related to all of our share-based payments that we recognized for the three and nine months ended September 30, 2018 and 2017 were as follows (in thousands):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2018		2017		2018		2017
Selling, general and administrative	$	2,194	$	591	$	3,913	$	1,950
Research and development		801		282		1,734		978
Total stock-based compensation expense	$	2,995	$	873	$	5,647	$	2,928

Summary of weighted-average assumptions relating to options granted pursuant to equity incentive plans


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2018		2017		2018		2017
Risk-free interest rate	2.9	%	2.1	%	2.7	%	2.2	%
Expected term (in years)	6.0		6.2		6.7		6.7
Dividend yield	0.0	%	0.0	%	0.0	%	0.0	%
Expected volatility	67.9	%	64.4	%	65.1	%	63.2	%

Summary of weighted-average assumptions used to calculate fair value of purchase rights granted under Employee Stock Purchase Plan


	Nine Months Ended
	September 30,
	2018		2017
Risk-free interest rate	2.4	%	0.6	%
Expected term (in years)	1.3		1.8
Dividend yield	0.0	%	0.0	%
Expected volatility	66.2	%	64.6	%